This paper will briefly compare the effect of SGLT2is and GLP-1 RAs to that of the SGLT1/2 inhibitor sotagliflozin on the incidence of MI and stroke in patients with type 2 diabetes and further postulate mechanisms associated with SGLT1 inhibition that could account for these findings. This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.